Sun Pharmaceutical Industries, country’s third largest drug maker by sales aims revenue growth of 18-20% for the current fiscal year ending March 2014. It is planning to invest Rs 800 crore on capital expenditure and file about 25 generic drug applications for approval in the United States.
The entity’s sales rose by 31.8% in the March quarter over the year-ago period to Rs 3,071.5 crore, and its gross margin rose as material costs increased by only 7.9%. While, the profit was boosted by higher other income and lower tax rate at 13.8%.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: